Registration Dossier

Toxicological information

Developmental toxicity / teratogenicity

Currently viewing:

Administrative data

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2019

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Deviations:
yes
Remarks:
see Section: Any ather information on materials and methods
GLP compliance:
yes
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
Disodium 4,4'-bis[(4-anilino-6-morpholino-1,3,5-triazin-2-yl)amino]stilbene-2,2'-disulphonate
EC Number:
240-245-2
EC Name:
Disodium 4,4'-bis[(4-anilino-6-morpholino-1,3,5-triazin-2-yl)amino]stilbene-2,2'-disulphonate
Cas Number:
16090-02-1
Molecular formula:
C40H38N12Na2O8S2
IUPAC Name:
disodium 5-{[4-(morpholin-4-yl)-6-(phenylamino)-1,3,5-triazin-2-yl]amino}-2-[(E)-2-(4-{[4-(morpholin-4-yl)-6-(phenylamino)-1,3,5-triazin-2-yl]amino}-2-sulfonatophenyl)ethenyl]benzene-1-sulfonate
Test material form:
solid: particulate/powder

Test animals

Species:
rat
Strain:
Wistar
Remarks:
CRL
Details on test animals or test system and environmental conditions:
Selection of animal species: laboratory rat has been chosen because our testing laboratory has long experience with this species and because rat is recommended according to the test guideline
Strain: Wistar CRL (SPF quality - guaranteed)
Supplier: Charles River SPF breeding, supplied via VELAZ s.r.o., Lysolajské údolí 15/53, 165 00 Prague 6, Czech Republic, RČH CZ 11760500
Sex: sexually adult females (males – only for mating)

Total number of animals: 23 probably pregnant females for each dose level (total number of animals before mating: 100 females and 25 males)
Acclimatization: 13 days
Age at start of the study: 12 weeks
Housing conditions: SPF conditions
Light cycle: 2 hour light/12 hour dark
Microclimate: 22±3 °C, relative humidity 30–70 %

Animal per cage: before mating 2 rats of the same sex in one cage,
during mating period one male and two females in one cage were housed.
pregnant females were then placed individually.
Bedding: sterilized clean shavings of soft wood or sterilized LIGNOCEL (raw material - spruce; producer: J.Rettenmaier&söhne, Germany).
Food: complete pelleted diet for rats and mice in SPF breeding (Altromin Spezialfutter) was used.
Manufacturer: Altromin Spezialfutter GmbH & Co. KG, Germany. Diet was sterilized before using.
Water: free access to drinking water (water ad libitum).
Water quality corresponded to Regulation No. 252/2004 Czech Coll. of Law, Health Ministry. Quality standard ČSN 757 111.
Selection of animals: pregnant females were randomly assigned to the experimental groups after determination of pregnancy.
Identification of animals: the animals were identified by the colour marks (colour for veterinary usage) on their fur, each cage was marked with the number of animals, sex, number of cage, name and dose level of the test item.

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
water
Details on exposure:
VEHICLE
Batch No.:1902220150, 1903260235, 1905170334
Expiration: 2/2021, 2/2021, 5/2021
Manufacturer: Ardeapharma Ševětín, Czech Republic

CONCENTRATIONS
- Concentration Level 10 mg/10 mL:
The test item was weighed into glass beaker calibrated to 100 mL and dissolved in vehicle in ultrasonic bath for 5 min. After this the solution was stirred by magnetic stirrer (350 rpm) for 10 minutes.
- Concentration Level 1000 mg/10 mL:
The test item was weighed into glass beaker calibrated to 100 mL and dissolved in vehicle (ca 80 % of total volume) in ultrasonic bath together with occasional mixing by glass rod for 10 minutes. After this the glass beaker was diluted to mark by vehicle and the application form was stirred by magnetic stirrer (400 rpm) for 15 min.

The beaker with test item was during dissolving, homogenisation and stability measuring covered by alluminium foil due to possible light unstability of test item. This measure is recommended for further test item application form preparation.
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
Stability and homogeneity were determined by means of measuring of a peak area of the test item by a high-performance liquid chromatography based on a method developed at the test facility.
Homogeneity of the application forms was checked by determination of a peak area of the test item in three places of application form (at the bottom, in the middle and on the surface).
Stability of the application forms was checked by analyses of the application forms within 120 min (at the time 0, 30, 60, 90 and 120 min). Time interval 0 min represents for concentration 10 mg/ 10mL the time after 5 minutes dissolving in ultrasonic bath and 10 minutes of mixing by magnetic stirrer (350 rpm) and for concentration 1000 mg/10mL the time after 10 minutes dissolving in ultrasonic bath and 15 minutes of mixing by magnetic stirrer (400 rpm).

Results of Analysis
It follows from the results of analyses (homogeneity and stability) that the both application forms (10 mg and 1000 mg /10 mL) of the test item at defined laboratory conditions (laboratory temperature, preparation of solution by defined manner) are homogenous and stable at least for 120 minutes from the finalization of application form preparation.
Details on mating procedure:
After acclimatization females were mated with males (1 male and 2 females). Vaginal smears were carried out daily in the morning to control fertilization (first time: 24 hours after
the first removing to male). Presence of sperms was examined. Day 0 of pregnancy was the day on which sperms in vaginal smears were observed. Pregnant females were randomly
distributed to experimental groups.
Frequency of treatment:
daily - 7 days per week at the same time (8.00 – 10.00 am)
Duration of test:
Exposition lasted from implantation (the 5th day after fertilization) to one day prior to the day of scheduled euthanasia (the 19th day after fertilization).

Doses / concentrationsopen allclose all
Dose / conc.:
100 mg/kg bw/day
Dose / conc.:
300 mg/kg bw/day
Dose / conc.:
750 mg/kg bw/day
No. of animals per sex per dose:
23 probably pregnant females for each dose level
Male rats serve only for mating (they are not administered by the test item and examined)
Control animals:
yes, concurrent vehicle
Details on study design:
Females were without feed two hours before application and two hours after application of the test item.

Dose selection rationale:
The dose levels for study – 100, 300 and 750 mg/kg/day - have been chosen with respect to the results of DRFE and to other toxicological data collected within category.

Examinations

Maternal examinations:
- Examination of vaginal smears of females
Each morning in the mating period vaginal smears were prepared from all mated females. These smears were stained and examined microscopically for presence of spermatozoa. Day 0 of pregnancy was the day when sperms were observed.

- Body weight of females
The body weight of pregnant females was recorded on automatic balances with group mean computing module. First weighing was performed on the 1st day of pregnancy and then on the 5th, 8th, 11th, 14th, 17th and 20th day of pregnancy. Weight increments were computed as a mean per group (in grams).

- Food consumption of females
Food consumption was determined at three-day intervals; it coincided with the terms of body weight recording.

- Mortality of females
All rats were examined for vitality or mortality changes daily during the acclimatization, mating and pregnancy.

- Health condition control of females
The health condition was controlled daily during the acclimatization period, during the mating period and during pregnancy. Pre-experimental control of all females was performed to ensure that only the females exhibiting normal behavioral activity would be entered into the study. In administration period this observation was performed before application and immediately after application.

- Clinical observations of the females
During the administration period clinical observation was made in order to record possible clinical effect of the test item application and all changes in behavior of females. Females were observed in natural conditions in their cages after application - once a day at the similar time each day.

- Determination of thyroid hormones
The blood samples for this examination were taken from orbital plexus by glass micropipette under the light ether narcosis on the 20th day of pregnancy. The blood serum samples were prepared by spontaneous coagulation and they were centrifuged 10 minutes in centrifuge and then were serum samples frozen. Blood samples from the pregnant females were assessed for serum levels of thyroid hormones (T3, T4, TSH) by ELISA kit.

-Biometry and histopathological examination of thyroid gland
During macroscopic examination the thyroid glands were removed from all pregnant females and were preserved in fixation medium. The thyroid weights were determined after fixation. For histopathological processing the routine histological paraffin technique with synoptic haematoxylin-eosin staining was used. The histopathology was performed in the control and high dose group. Treatment-related changes were not observed at the high dose group therefore detailed histological examination of thyroid gland was performed only for all high dose and control females.

- Biometry of uterus and macroscopical examination of females
On the 20th day of pregnancy the females were narcotised and sacrificed by cutting the neck spine and medulla. The revision of the external surface of the body was performed.
During macroscopic all orifices, the cranial, thoracic and abdominal cavities were examined and uterus (incl. the cervix) was removed and weighed.
In gravid uterus number of viable foetuses, number of dead foetuses, number of early resorption (implantation without recognizable embryo/foetus) and number of late resorption (dead embryo or foetus with external degenerative changes) were recorded. The number of corpora lutea of both ovaries were found out.
Uteri of non-pregnant females were examined to confirm the non-pregnant status (by the help of ammonium sulphide staining)
The absolute weight of uterus was recorded. Afterwards the relative weight of uterus was computed according to the following formula:

Relative weight of uterus = (absolute weight of uterus ×100)/(body weight of female on 20th day)

Also the correction of body weight was performed according to the following formula:

Corrected body weight = body weight of female on 20th day - weight of uterus

Ovaries and uterine content:
In uterus number of viable foetuses, number of dead foetuses and number of resorptions (implantation without recognisable embryo/foetus or dead embryo or foetus with external degenerative changes) were recorded.
Number of corpora lutea on ovaries was also recorded.
Preimplantation and postimplantation losses were calculated from number of implantations (number of foetuses plus number of resorptions), corpora lutea and resorptions.

Preimplantation loss – IUDE (Intra Uterine Death Early):
Preimplantation loss = (corpora lutea - implantations)/(corpora lutea) ×100

Postimplantation loss – IUDL (Intra Uterine Death Late):
Postimplantation loss = resorptions/implantations ×100
Fetal examinations:
Sex, individual body weights and anogenital distance (AGD) of foetuses were recorded. A digital caliper was used for AGD measurements. Corrected AGD was calculated according to the formula: AGD divided by the cube root of body weight.

Each foetus was examined for external alterations:
- symmetry of fore and hind limbs
- number of fingers
- closing or opening of eye fissures and external auditory canal
- symmetry of head
- integrity of superior palatum
- status of umbilicus
- genital papilla

One half of each litter (one half of female and male foetuses) was examined for soft tissue alterations using careful gross dissection.
Second half of each litter was processed and microscopically examined for skeletal and cartilage alterations.
Single staining displayed only ossified skeletal structures was used: the foetuses were fixed in ethanol, macerated in potassium hydroxide solution, stained with Alizarin red and placed in glycerine-based solution.
The skeletal examination was performed using a stereomicroscope and included examination of skull, clavicle, scapula, sternebra and sternum, ribs, vertebrae, pelvic girdle, forelimb/hindlimb.

Physiological appearance:
- Vertebrae - cervical vertebrae: 7, thoracic v.: 13, lumbar v.: 6, sacral v.: 4.
- Ribs:
“True ribs”:7 vertebrosternal ribs, upper thoracic ribs that are attached directly to the sternum
“False ribs”:3, long costal cartilage, but not articulated with sternum
“False floating ribs”:3, short costal cartilage, and not articulated with sternum
- Sternum: 6 ossification sites


Statistics:
For statistical evaluation the software Statgraphic® Centurion (version XV, USA) was used. The data from control group were compared with data from treated groups.

The parametric tests were used for statistical evaluation of:
•body weight of females (5th, 8th, 11th , 14th , 17th , 20th day of pregnancy)
•corrected body weight (subtraction weight of uterus from surgery body weight of females)
•food consumption (per interval)
•mean weight of foetuses (males, females, both sex)
•anogenital distance
•thyroid hormones
•biometry of thyroid gland (absolute and relative weight )
•biometry of uteri (absolute and relative weight )
•preimplantation (IUDE) and postimplantation (IUDL) losses

As the first step the test for normality (Shapiro-Wilk test) was performed. If the data were not normally distributed the transformation of data was performed (Box-Cox transformation). If the data were not normal distributed after transformation the non-parametric tests (Kruskal-Wallis Test and Mann-Whitney test) for comparison of the medians were performed.
If data were normally distributed after transformation, the Variance check (Levene’s test) to verify standard deviations within each group was used. One-Way ANOVA (probability level 0.05) was used to detect whether there were any significant differences amongst the means and then the post hoc statistical testing (Fisher's least significant difference - LSD test) for only statistical significant differences was performed.

The non-parametric tests were used for statistical evaluation of following parameters:
•number of corpora lutea, number of implantations, number of resorptions
•number of live foetuses (males, females, both sex)
•number of dead foetuses
The two-groups Mann-Whitney test (probability level 0.05) was applied.

The categorical data (skeletal foetal findings) were analyzed using the generalized linear mixed models with Poisson distribution.

Results and discussion

Results: maternal animals

General toxicity (maternal animals)

Clinical signs:
no effects observed
Description (incidence and severity):
No clinical changes indicating the dysfunction of organism were found in the control and treated groups during the whole study.
Dermal irritation (if dermal study):
not examined
Mortality:
no mortality observed
Body weight and weight changes:
no effects observed
Description (incidence and severity):
Only females who were found pregnant on the 20th day of gravidity (females with live foetuses) were used for calculation of mean body weights. The statistical evaluation was performed from the 5th to 20th day of pregnancy.
The body weights of treated females at all dose levels were similar to the control group during whole study. No statistically significant changes were observed. The body weight increments at all dose levels were comparable with the body weight increment of the control females.
Food consumption and compound intake (if feeding study):
no effects observed
Description (incidence and severity):
Only females which were found to be pregnant 20th day of gestation (females with live foetuses) were used for calculation of mean food consumption, although is it is not a feeding study. The statistical evaluation was performed from the 5th to 20th day of pregnancy.
The average food consumption of all treated groups was comparable with the control group during whole study. Statistically significant differences were not detected.
Food efficiency:
not examined
Water consumption and compound intake (if drinking water study):
not examined
Ophthalmological findings:
not examined
Haematological findings:
not examined
Clinical biochemistry findings:
not examined
Urinalysis findings:
not examined
Behaviour (functional findings):
no effects observed
Immunological findings:
not examined
Organ weight findings including organ / body weight ratios:
no effects observed
Description (incidence and severity):
The uteri of all females were weighed, but only females which were found to be pregnant 20th day of gestation were used for calculation of mean weight of uterus. The absolute weight of uterus was recorded and the relative weight of uterus was computed. The statistical evaluation of absolute and relative weight of uterus was performed.
The mean absolute and relative weights of uterus at all dose levels were comparable with the control group. Statistically significant differences in uterus biometry were not detected in females of any dose level.
The thyroid glands of all females were weighed (after fixation), but only females which were found to be pregnant 20th day of gestation were used for calculation of mean weight of thyroid gland. The absolute weight of thyroid gland was recorded and the relative weight of thyroid gland was computed. The statistical evaluation of absolute and relative weight of thyroid glands was performed.
Statistically significant differences of thyroid weights were not detected in females of any dose level. Absolute and relative weights of the thyroid glands were similar in the treated and control females.
Gross pathological findings:
no effects observed
Description (incidence and severity):
Macroscopic examination was performed in all females (including females without foetuses). The uterus dilatation (the change probably related with oestrous cycle) was detected only in one non-pregnant female at the middle dose level. No finding related with treatment was noted at necropsy in treated females.
The irregularly colored livers were recorded in three females at the middle dose level and in three females at the highest dose level.
Histopathological findings: non-neoplastic:
no effects observed
Description (incidence and severity):
The livers with irregular coloration (recorded in three females at the middle dose level and in three females at the highest dose level) were collected and processed for histological examination. Histological examination revealed no pathological changes. This macroscopic finding was probably related to the animal euthanasia.
The histopathology of the thyroid glands was performed for the control females and high dose in first instance. Histological examination of thyroid glands revealed no pathological changes. Because the treatment related changes were not recorded, histopathology of thyroid gland at doses 100 and 300 mg/kg/day was not performed.
Other effects:
no effects observed
Description (incidence and severity):
Blood samples from the females which were found to be pregnant 20th day of gestation were assessed for serum levels of thyroid hormones (T3, T4, TSH).
No statistically significant differences were recorded in serum levels of thyroid hormones T3 and T4 in females from treated groups against control females. Serum level of TSH was slightly decreased in females at the middle dose level, but also without statistical significance.

Maternal developmental toxicity

Pre- and post-implantation loss:
no effects observed
Description (incidence and severity):
Preimplantation losses (IUDE) and postimplantation losses (IUDL) in all treated groups were similar or decreased in comparison with control group. Statistically significant differences were not detected.
Total litter losses by resorption:
no effects observed
Description (incidence and severity):
The numbers of resorptions were in all dose levels lower than in control group.
Dead fetuses:
no effects observed
Description (incidence and severity):
Dead foetuses were found out in treated groups as well in control group (2 – 0 – 2 – 0). The highest number of foetuses was recorded in high dose level. The average total number of foetuses in litter was well balanced in all groups.
Changes in pregnancy duration:
no effects observed
Changes in number of pregnant:
no effects observed

Effect levels (maternal animals)

Dose descriptor:
NOAEL
Effect level:
ca. 750 mg/kg bw/day
Based on:
test mat.
Basis for effect level:
behaviour (functional findings)
body weight and weight gain
clinical biochemistry
clinical signs
dead fetuses
effects on pregnancy duration
food consumption and compound intake
gross pathology
histopathology: non-neoplastic
maternal abnormalities
mortality
necropsy findings
number of abortions
organ weights and organ / body weight ratios
pre and post implantation loss
total litter losses by resorption

Maternal abnormalities

Key result
Abnormalities:
no effects observed

Results (fetuses)

Fetal body weight changes:
no effects observed
Description (incidence and severity):
The mean body weight of foetuses was decreased at the middle dose level compared to the control group. Although the variation between individual body weight of foetuses at this dose level against control foetuses was observed, this difference was not statistically significant. Male foetuses were heavier than females in all groups.
Reduction in number of live offspring:
no effects observed
Description (incidence and severity):
The statistical evaluation was performed for the number of live foetuses, the number of live male foetuses, the number of live female foetuses and number of dead foetuses per litter. Statistically significant differences of above mentioned parameters were not detected in any dose level.
Changes in sex ratio:
not examined
External malformations:
no effects observed
Description (incidence and severity):
Examination of symmetry of fore and hind limbs, number of fingers, closing or opening of eye fissures and external auditory canal, symmetry of head, integrity of superior palatum, status of umbilicus and genital papilla were performed.
Dead foetuses were found out in treated groups as well in control group (2 – 0 – 2 – 0). One foetus without tail was recorded at the middle dose level. No other external changes were recorded.
Skeletal malformations:
no effects observed
Description (incidence and severity):
Examination of foetal cranium revealed mainly incomplete ossification of cranial bones. By incomplete ossification were affected mostly parietal bone, interparietal bone, supraoccipital bone, arcus zygomaticus, squamous part of temporal bone, less frequently frontal bone, basisphenoid and nasal bone. The portions of litters with incomplete ossification of cranial bones were lower or similar in the treated groups in comparison with the control group, except the incidence of incomplete ossification of parietal bone and interparietal bone. The highest portions of litters with these findings were recorded at the dose level 300 mg/kg/day. The frequency of holes in the supraoccipital bone was similar or lower at dose levels compared to the control group. The portions of litters with the bipartite ossification of supraoccipital bone were 4.76 % – 9.09 %. – 5.56 % – 0.00 %. Other changes of foetal cranium were found only sporadically.
During examination of foetal skeleton incomplete ossification of ossification sites of sternebra was recorded. The incidence of incomplete ossification of ossification sites on sternebra was very common in treated groups and also control group (100.00 % – 100.00 % – 94.44 % – 95.24 %). The portions of litters with unossified ossification sites of sternebra (85.71 % – 68.18 % – 77.78 % – 61.90 %) were slightly decreased at dose levels compared to the control group. Less often, bipartite ossification of ossification sites was found on sternebra (14.29 % – 13.64 – 0.00 – 4.76 %).
Examination of vertebrae revealed mainly dumbbell ossification of vertebrae thoracic centrum. The portions of litters with dumbbell ossification of vertebrae thoracic centrum were similar in the treated groups and control group (80.95 % – 90.91 % – 88.89 % – 90.48 %). Less frequent was the finding of bipartite ossification and asymmetric ossification of vertebrae thoracic centrum. The portions of litters with bipartite ossification of vertebrae thoracic centrum were 23.81 % – 27.27 % – 33.33 % – 14.29 %.
Anomaly of ribs – supernumerary site and wavy ribs were recorded. The portions of litters with ribs-supernumerary site (85.71 % – 63.64 % – 55.56 % – 57.14 %) and wavy ribs (42.86 % – 27.27 % – 33.33 % – 23.81 %) were lower at all dose levels compared to the control group. Other skeletal changes were found out rarely.
The statistical evaluation of skeletal findings was performed. The data from control were compared with data from treated groups using the generalized linear mixed models with Poisson distribution. No statistically significant differences were recorded.
Visceral malformations:
no effects observed
Description (incidence and severity):
Placing and morphology of organs and big vessels were reviewed during examination of internal alterations. No findings were found at all dose levels and control group.
Other effects:
no effects observed
Description (incidence and severity):
The anogenital distance (AGD) of each foetus was measured by digital caliper on 20th of pregnancy of females and the corrected AGD was calculated. The statistical evaluation was performed for AGD and corrected AGD of male and female foetuses.
The statistically significantly increased male AGD was recorded at the lowest and highest dose levels. The corrected male AGD was statistically significantly increased only at the lowest dose level.
The AGD and corrected AGD of female foetuses at dose levels were comparable with control.

Effect levels (fetuses)

Dose descriptor:
NOAEL
Effect level:
ca. 750 mg/kg bw/day
Based on:
test mat.
Sex:
male/female
Basis for effect level:
fetal/pup body weight changes
changes in litter size and weights
changes in postnatal survival
external malformations
skeletal malformations
visceral malformations

Fetal abnormalities

Abnormalities:
no effects observed

Overall developmental toxicity

Developmental effects observed:
no

Any other information on results incl. tables

From the results of analyses (homogeneity and stability), it was evident that the both application forms (10 mg and 1000 mg /10 mL) of the test item at defined laboratory conditions (laboratory temperature, preparation of solution by defined manner) are homogenous and stable at least for 120 minutes from the finalization of application form preparation.

Applicant's summary and conclusion

Conclusions:
The NOAEL (No Observed Adverse Effect Level) for toxicity in PREGNANT FEMALES was established as 750 mg/kg/day. This NOAEL value is based on no mortality of females, no changes in health condition status, no pathological findings in the dams, no dose related changes in reproduction parameters.

The NOAEL (No Observed Adverse Effect Level) for PRENATAL DEVELOPMENT was established as 750 mg/kg/day. This NOAEL is based on no altered growth and no serious structural abnormality found in treated foetuses.
Executive summary:

The test item was tested for prenatal developmental toxicity following the OECD Test Guideline 414.

 

Study performance

Before the start of experiments with laboratory animals the stability and homogeneity of application form were determined at the test facility.

A dose-range finding experiment (DRFE) was performed to determine the dose levels for the main study.

Males from DRFE were used after mating for determination of toxicokinetic properties of the test item.

 

Wistar rat females and males of SPF quality were used for testing. After acclimatization the females were mated with males in the main study.

The test item was then administered to pregnant females by gavage, daily from the 5thto the 19thday of pregnancy, at dose levels of 0, (vehicle), 100, 300 and 750 mg/kg/day. T

 

The health condition, clinical status after application, body weight and food consumption of maternal animals were monitored during developmental toxicity study. On the day of necropsy, blood was collected from pregnant females to determine thyroid hormone levels (T3, T4, TSH). On the 20th day of pregnancy the maternal animals were euthanized, the uterine contents were examined and the foetuses were assessed for changes on soft tissues and skeleton. The foetuses were weighed and the anogenital distances were measured. The thyroid glands were removed from the females and histological examination was performed.

 

Results

There were no unscheduled deaths of females during the study at any dose level.

No adverse changes of health condition and no clinical symptoms of intoxication were found in females at any dose level after administration of the test item.

During the control of body weight increments and food consumptionin pregnant females at all dose levels, toxicologically significant treatment-related effects were not detected. Evaluation of uterine weights (absolute and relative weight of uterus) did not reveal toxicologically significant treatment-related effects.

Macroscopical structure of organs of pregnant females and values of reproduction parameters (number of females with live foetuses, number of live and dead foetuses, early and late resorptions and sex ratio of foetuses) were unaffected by treatment with the test item.

Examination of the thyroid glands, in terms of absolute and relative weight of thyroid gland, histological examination of thyroid gland and serum levels of thyroid hormones,did not reveal any changes associated with the application of the test item. Only serum level of TSH was slightly decreased in females at the middle dose level, but without statistical significance.

 

Test item-related foetal mortality was not evident at any dose level. The foetal body weight was statistically insignificantly decreased at the middle dose level.The mean anogenital distance of male foetuses was statistically significantly increased at the lowest and highest dose levels compared to the control. The corrected male AGD was statistically significantly increased only at the lowest dose level. In male foetuses we did not observe the feminization effect (shortening male AGD).The mean AGD and corrected AGD of female foetuses at the dose levels was balanced with control.

Detailed necropsy of foetuses did not reveal increase of external and visceral variations and malformations at any dose level.

Foetal skeletal examination revealed no statistically significant differences between treatment groups and control group.

 

The NOAEL for toxicity in pregnant females was established as 750 mg/kg/day.

This value was based on no mortality of females, no changes in health condition status, no pathological findings in the dams, no dose related changes in reproduction parameters.

 

The NOAEL for prenatal developmental was established as 750 mg/kg/day.

This NOAEL is based on no altered growth and no serious structural abnormality found in treated foetuses.